NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Actuate Therapeutics, Inc. Common stock (ACTU) Stock Analysis

Actuate Therapeutics, Inc. Common stock (ACTU) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

ACTU

$1.48

+$0.11 (+8.03%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ACTU with… →

ACTU Key Statistics

As of Sep 4, 2026
Trading
Open
$1.45
Previous Close
$1.37
Day's Range
1.33–1.73
52-Week Range
0.90–8.55
Volume
1.32M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.96
Valuation
Market Cap
$35.54M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.96
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$22.23M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
24.01M
1-Year Return
−83.03%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
363.69K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ACTU Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−75.82%
2025−23.12%
2024 (partial year)−7.55%

As of September 4, 2026.

ACTU Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$22.23M—
2024$0.00−$27.29M—
2023$0.00−$24.74M—
2022$0.00−$20.16M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$22.50M−$22.23M—
2024$0.00—−$25.16M−$27.29M—
2023$0.00—−$24.97M−$24.74M—
2022$0.00—−$20.21M−$20.16M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ACTU Valuation vs Biotechnology Median

Median of 656 stocks
MetricACTUBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Actuate Therapeutics, Inc. Common stock (ACTU) at $35.54M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 12 employees.

The 52-week range on file runs from $0.90 to $8.55. ACTU last closed at $1.48 on September 4, 2026. That is +$0.11 (+8.03%) against the previous close. The latest close sits 64.44% above that 52-week low.

Financial Health

In fiscal 2025, Actuate Therapeutics, Inc. Common stock reported revenue of $0.00. The same year closed with a net loss of $22.23M. Profit margin runs at 0%. Trailing earnings per share are −0.96.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Beta against the wider market is reported at 0.96. Annualized volatility over the trailing 2 years is 93.15%. The trailing one-year price return is −83.03%. The stored price history starts on August 13, 2024, and the total return since then is −82.81%.

Growth & Income

No dividend is on file for ACTU.

The record holds one complete calendar year, 2025, which returned −23.12%. So far in 2026 the price is −75.82%.

Peer Comparison

Actuate Therapeutics, Inc. Common stock (ACTU) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Actuate Therapeutics, Inc. Common stock ACTU $35.54M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Actuate Therapeutics, Inc. Common stock has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Actuate Therapeutics, Inc. Common stock

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as neuroblastoma and pediatric leukemias. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas.

Visit website →